FindTrial
Sign In

Rescue Medications

DRUG10 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Cervical CancerEndometrial CancerEsophageal CancerEsophageal NeoplasmsGastroesophageal AdenocarcinomaGastroesophageal CancerGastroesophageal JunctionLung Neoplasm

Phase 1

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RecruitingNCT06445972
Merck Sharp & Dohme LLCEsophageal Cancer, Esophageal Neoplasms, Gastroesophageal Adenocarcinoma +1
Start: 2024-08-07End: 2030-08-08Target: 210Updated: 2026-04-02
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
Active, not recruitingNCT06460961
Merck Sharp & Dohme LLCNeoplasm Metastasis
Start: 2024-07-14End: 2027-07-13Target: 168Updated: 2025-12-31
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
RecruitingNCT07227597
Merck Sharp & Dohme LLCSmall Cell Lung Cancer Extensive Stage
Start: 2026-01-29End: 2030-12-30Target: 170Updated: 2026-03-30
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
RecruitingNCT07286149
Merck Sharp & Dohme LLCLung Neoplasm Malignant
Start: 2026-03-23End: 2037-05-06Target: 190Updated: 2026-03-16

Phase 2

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
RecruitingNCT06780098
Merck Sharp & Dohme LLCLung Neoplasm
Start: 2025-05-28End: 2032-03-02Target: 144Updated: 2026-04-01
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
RecruitingNCT06979596
Merck Sharp & Dohme LLCMalignant Neoplasm
Start: 2025-08-11End: 2027-11-04Target: 250Updated: 2026-04-02

Phase 3

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Active, not recruitingNCT06132958
Merck Sharp & Dohme LLCEndometrial Cancer
Start: 2023-12-06End: 2028-01-10Target: 710Updated: 2026-04-03
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
Active, not recruitingNCT06356311
Merck Sharp & Dohme LLCGastroesophageal Cancer
Start: 2024-05-03End: 2027-05-06Target: 450Updated: 2026-02-27
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
RecruitingNCT07216703
Merck Sharp & Dohme LLCCervical Cancer
Start: 2026-01-19End: 2031-10-29Target: 1023Updated: 2026-03-20
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
RecruitingNCT07318558
Merck Sharp & Dohme LLCOvarian Cancer, Ovarian Neoplasms
Start: 2026-02-16End: 2033-02-25Target: 900Updated: 2026-04-02

Related Papers

KEYMAKER-U06: Phase 1/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma.
Journal of Clinical Oncology2025-01-27